Welcome to our dedicated page for Worthington Steel news (Ticker: WS), a resource for investors and traders seeking the latest updates and insights on Worthington Steel stock.
Worthington Steel, Inc. reports company news centered on value-added steel processing, quarterly and annual operating results, dividends, conference calls and corporate updates. Its business updates describe carbon flat-rolled steel processing, electrical steel laminations, tailor welded products and related capabilities such as galvanizing, pickling, configured blanking, specialty cold reduction and lightweighting.
Worthington Steel news also includes disclosures about material agreements, capital-structure matters and shareholder-related developments when they affect the company’s public reporting. The recurring news record reflects a NYSE-listed Ohio company with steel-processing operations across the United States and international markets.
Next.e.GO Mobile SE has signed a memorandum of understanding (MOU) with Trafigura Pte. Ltd. to establish a long-term supply chain management agreement, focusing on the supply of aluminum and battery metals including lithium, cobalt, and copper. Commencing in January 2024 and lasting at least five years, this collaboration aims to boost e.GO’s supply chain reliability and support its decentralized growth strategy. The partnership also includes provisions for a supply credit facility and emphasizes sustainability through carbon declaration via the Agora platform. This move is pivotal as e.GO prepares for its upcoming business combination with Athena Consumer Acquisition Corp. (NYSE: ACAQ).
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in two upcoming investor conferences. The company aims to enhance surgical procedures through innovative robotics technology.
The first event is the Cowen 43rd Annual Healthcare Conference, featuring a fireside chat on March 8th at 9:50 a.m. ET. The second is the Oppenheimer 33rd Annual Healthcare Conference, with a virtual presentation scheduled for March 14th at 1:20 p.m. ET. Live and archived versions of these presentations will be available on the company's website.
Kaleyra reported record revenues of $93.7 million for Q4 2022, a growth of 4.1% year-over-year, leading to a full-year total of $339.2 million, up 27% YoY. The company announced the implementation of a 2023 restructuring and cost reduction program aimed at reducing cash payroll costs by over 15%.
Despite the revenue growth, Kaleyra experienced a net loss of $57.8 million in Q4 due to a significant impairment loss on intangible assets. The gross profit also decreased to $17 million, reflecting higher customer onboarding costs.
Vicarious Surgical reported a cash burn of $67 million for 2022, meeting its objective, and announced initiatives to extend its cash runway. The company expects 2023 cash burn between $55-$65 million. Vicarious Surgical's operating expenses surged to $80.1 million in 2022 versus $38.2 million in 2021, with an adjusted net loss of $78.8 million, or $0.65 per share. Despite a GAAP net income of $5.2 million for the year, the company reported significant losses. Notable achievements include the completion of the Beta 2 robotic system and partnerships with major healthcare providers, enhancing its market position.
Kaleyra, Inc. (NYSE: KLR, KLR WS) will announce its Q4 and full-year 2022 financial results on February 15, 2023, at 4:30 PM ET. The call will be hosted by CEO Dario Calogero, CFO Giacomo Dall'Aglio, and Investor Relations VP Colin Gillis, featuring a presentation followed by a Q&A session. Interested parties can join the call by dialing 1-855-327-6837 (US) or 1-631-891-4304 (international) ten minutes before the start. A replay will be available post-call until February 22, 2023, via toll-free number 1-844-512-2921. Kaleyra provides CPaaS services to diverse sectors globally, managing vast messaging traffic securely.
Tailwind Acquisition Corp. (NYSE American: TWND, TWND.U, TWND WS) has completed its business combination with NUBURU, Inc., an innovator in industrial blue laser technology. NUBURU is now publicly listed, with its stock trading under the ticker 'BURU' starting February 1, 2023. The CEO of NUBURU, Dr. Mark Zediker, expressed optimism about gaining capital access and accelerating product development. The combined entity aims to strengthen its market position in sectors such as 3D printing and aerospace, highlighting innovations like the new BL-series blue lasers showcased at Photonics West.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on February 13, 2023. A conference call will follow at 4:30 p.m. ET for management to discuss the results. Investors can join by calling +1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. The company develops advanced surgical robotics aimed at improving the efficiency of procedures and reducing costs, using proprietary technology to perform minimally invasive surgeries.
Summary not available.
Sky Harbour Group Corporation (NYSE American: SKYH, SKYH WS) announced a significant expansion at Dallas's Addison Airport (ADS), doubling its footprint to approximately 195,000 rentable square feet. The CEO, Tal Keinan, highlighted Dallas as a key market for business jets, enhancing the airport's attractiveness for private and corporate flight departments. Sky Harbour operates campuses at Houston's Sugar Land Regional Airport and Nashville International Airport, with a Miami campus set to open soon. New facilities are also in development at Denver Centennial and Phoenix Deer Valley Airports.
ROSS Acquisition Corp II (NYSE: ROSS,WS) has entered into a definitive agreement to merge with APRINOIA Therapeutics, a clinical-stage biotech focused on neurodegenerative diseases. The transaction is valued at $280 million, with funding aimed at advancing APRINOIA's therapeutic programs, including its lead product, APN-1607. The merger, expected to close in the first half of 2023, will create a publicly traded entity on Nasdaq or NYSE. APRINOIA holds agreements with major biotech firms such as Biogen, and anticipates significant market opportunities in treating Alzheimer’s Disease, which affects an estimated 10 million individuals in China alone.